GlassScriptPhysician profile
Marwan S Saad
NPI 1881054328
$56,951.00
in general payments reported to CMS, 2019-2025
10 companies · $24K in 2025
The $24K reported for 2025 was more than what 93% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $944 · 2020: $22K · 2021: $826 · 2022: $4,706 · 2023: $3,578 · 2024: $1,093 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Travel and Lodging: $6,043 · Food and Beverage: $4,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,250.00 |
| Travel and Lodging | $6,043.43 |
| Food and Beverage | $4,174.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $28,315.87 | 2019-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Medtronic Vascular, INC. | $21,224.63 | 2019-2020 | |
| Abbott Laboratories | $3,771.33 | 2020-2025 | Amplatzer Amulet, Epic, Mitraclip |
| Boston Scientific Corporation | $2,083.21 | 2019-2023 | Watchman Access System |
| Ancora Heart, INC. | $695.98 | 2023 | Accucinch |
| Medtronic, INC. | $437.20 | 2021-2023 | Corevalve Evolut R |
| Astellas Pharma US INC | $214.99 | 2019 | |
| Teleflex LLC | $167.10 | 2022-2023 | Manta |
| Alnylam Pharmaceuticals INC. | $21.43 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.26 | 2023 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marwan Saad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.